Seòmar agus comataidhean

Reporting mechanisms for uptake of the H1N1 vaccine are not yet consistent across all health boards, therefore accurate and comparable figures will not be available until the end of the vaccination programme. Overall, the vaccine uptake rate for all health boards across Scotland is 45.6% for the whole clinical at-risk group.

An analysis of the underlying health conditions suffered by people who have died from influenza A (H1N1) is reported and published weekly by Health Protection Scotland in their weekly situation report.

The total number of deaths in Scotland, as of midday 6 January, is 62. Of the 60 cases who died in hospital, at least 72% (43/60) were known to have underlying medical conditions including: diabetes (six), a respiratory condition (12), obesity (seven), renal/liver conditions (11), congenital abnormalities (nine), immunosuppression (seven), pregnancy (three) and a malignant illness (five). In some cases, there were multiple conditions present.

The estimated uptake rate so far for people under 65 years in a clinical at-risk group is 48.3%, among individuals aged 65 years and over in a clinical at-risk group the figure is 42.3% and among pregnant women it is 45.0%. Overall, this equates to 45.6% for the whole clinical at-risk group.

To date, an estimated 50.8% of eligible frontline health care staff have received the vaccination, and 32.1% of eligible frontline social care staff have been vaccinated.

Data is not held in GP systems on the number of individuals who are a household contact of an immunocompromised individual and therefore there is no reliable denominator for this population to determine uptake rates at a national level.

The Scottish Government Health Directorate (SGHD) and Health Protection Scotland (HPS) have worked closely with NHS boards on planning for local service delivery on a national level, and the SGHD and HPS continue to have frequent engagement with NHS boards to monitor the progress of the vaccination programme.

The second phase of the vaccination programme has now commenced and is offering vaccination to children over six months and under five years. It is expected that this will be completed by the end of January with some mop up activity into mid-February.

As acknowledged in the answer to the question S3W-29773 on 7 January 2010, the content and substance of each report held on NHS board websites has varied and has led to inconsistencies in the range of data being reported across NHS Scotland. The review of the structure and presentation of the HAI reporting template (HAIRT), currently being undertaken by a short-life working group led by NHS Scotland, is working to ensure consistency of reporting across all NHS boards. The revised HAIRT will be introduced from spring 2010 and will reinforce the requirement for specialty information to be included.

All answers to written parliamentary questions are available on the Parliament''s website, the search facility for which can be found at http://www.scottish.parliament.uk/Apps2/Business/PQA/Default.aspx.

The information is not held centrally. Health Protection Scotland (HPS) collate and publish Clostridium difficile surveillance statistics by NHS board on a quarterly basis. HPS data for 2009 is available up to and including September 2009. The HPS report for the quarter ending December 2009 will be published in April 2010.

Data for patients aged 65 and over in all healthcare settings for the periods January 2008 to December 2008 and January 2009 to September 2009 are as follows:

NHS Board	January 2008 to December 2008	January 2009 to September 2009
Ayrshire and Arran	560	335
Borders	115	68
Dumfries and Galloway	170	128
Fife	394	98
Forth Valley	458	116
Grampian	953	513
Greater Glasgow and Clyde	1395	532
Highland	150	98
Lanarkshire	715	214
Lothian	850	495
Orkney	21	21
Shetland	6	1
Tayside	524	328
Western Isles	14	6
National	6,325	2,953

Since January 2009, all NHS boards have been publishing hospital level data on Clostridium difficile. This can be accessed at:

http://www.scotland.gov.uk/Topics/Health/NHS-Scotland/19529/statistics/Local.

The at risk groups as announced on 13 August 2009 includes all people who have asthma that requires continuous or repeated use of systematic steroids or with previous exacerbations requiring hospital admission.

The H1N1 vaccination programme was launched on 21 October and proceeded with a phased roll out from this date. Health boards have indicated that vaccination has been offered to all those in the initial priority groups and a mop up exercise continues to take place to the end of January to ensure that everyone in the initial priority groups has been invited for vaccination.

It is anticipated that the vaccination of young children will be completed by the end of January, with some mop up activity into mid-February, to ensure all children aged over six months and under six years are invited for vaccination.

An estimated 7,991 children aged 0 to four years in Scotland contracted H1N1, experienced symptoms and were taken to see a GP. An estimated 21,036 children aged five to 14 years in Scotland also contracted H1N1, experienced symptoms and were taken to see a GP.

A total of 1,482 H1N1 laboratory confirmed individuals have been admitted to hospital. Where the age had been specified or was known, 255 (17.2%) were aged under five years.

NHS Scotland has now received 100% of the vaccine supply required to vaccinate all those in the initial priority groups and all children aged over six months and under five years. This means that 1,716,500 doses of pandemrix and 167,800 doses of celvapan have been delivered to health boards and GP practices across Scotland.